Clinical Trial Update: Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating chemotherapy plus tislelizumab as a bladder-sparing option for muscle-invasive bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Muscle-Invasive Bladder Carcinoma | Phase 2 | Status: UNKNOWN